The holiday period included Genmab’s discontinuation of acasunlimab.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
The group toplines a phase 2 win with Alphamedix.
And Treeline and HengRui also get in on the pan-RAS act.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
